Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 9/20 | 0.56 |
| ▸ | TNK2 | Q07912 | 7/20 | 0.56 |
| ▸ | JAK2 | O60674 | 4/20 | 0.56 |
| ▸ | SRC | P12931 | 4/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.54 |
| ▸ | ROS1 | P08922 | 2/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24255240 | 0.85 | JAK3 (0.58) | ALKTNK2JAK2SRCLRRK2 | |
| SCHEMBL24255302 | 0.84 | ALK (0.77) | ALKTNK2JAK2SRCLRRK2 | |
| SCHEMBL24255326 | 0.83 | TNK2 (0.64) | ALKTNK2JAK2SRCROS1 | |
| SCHEMBL26361478 | 0.80 | TNK2 (0.61) | ALKTNK2JAK2SRCLRRK2 | |
| SCHEMBL24255222 | 0.80 | TNK2 (0.75) | ALKTNK2JAK2SRCROS1 | |
| SCHEMBL26270495 | 0.79 | ALK (0.66) | ALKTNK2JAK2SRCLRRK2 | |
| SCHEMBL24255507 | 0.79 | LRRK2 (0.64) | ALKTNK2JAK2SRCLRRK2 | |
| SCHEMBL24258118 | 0.78 | ALK (0.67) | ALKTNK2JAK2SRCLRRK2 | |
| SCHEMBL24255315 | 0.77 | ALK (0.67) | ALKTNK2JAK2SRCLRRK2 | |
| SCHEMBL26361472 | 0.76 | TNK2 (0.49) | ALKTNK2JAK2SRCLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295129-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH | 2023-09-21 | — | — | US | disclosed |
| WO-2022036312-A2 | INHIBITORS OF ACK1/TNK1 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295129-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNK2, TNNI3K | ALK 272/4885TNK2 2/4885JAK2 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.